Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125263322 | 12526332 | 2 | F | 20160630 | 20160705 | 20160707 | PER | US-PFIZER INC-2016326636 | PFIZER | 69.00 | YR | M | Y | 91.00000 | KG | 20160707 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125263322 | 12526332 | 1 | PS | VIAGRA | SILDENAFIL CITRATE | 1 | 100 MG, UNK | 20895 | 100 | MG | FILM-COATED TABLET | ||||||||
| 125263322 | 12526332 | 2 | I | VIAGRA | SILDENAFIL CITRATE | 1 | 50 MG (100MG, HALF TABLET), 2X/DAY IN THE MORNING AND AT NIGHT | 20895 | 50 | MG | FILM-COATED TABLET | BID | |||||||
| 125263322 | 12526332 | 3 | I | VIAGRA | SILDENAFIL CITRATE | 1 | 200 MG (100MG, DOUBLE DOSE), UNK | 20895 | 200 | MG | FILM-COATED TABLET | ||||||||
| 125263322 | 12526332 | 4 | I | TERAZOSIN HCL | TERAZOSIN HYDROCHLORIDE | 1 | 10 MG, 1X/DAY | U | 0 | 10 | MG | CAPSULE | QD | ||||||
| 125263322 | 12526332 | 5 | I | FINASTERIDE. | FINASTERIDE | 1 | 5 MG, 1X/DAY IN THE MORNING | U | 0 | 5 | MG | TABLET | QD | ||||||
| 125263322 | 12526332 | 6 | C | OXYBUTYNIN CHLORIDE. | OXYBUTYNIN CHLORIDE | 1 | 5 MG, 1X/DAY | 0 | 5 | MG | TABLET | QD | |||||||
| 125263322 | 12526332 | 7 | C | BUPROPION HYDROCHLORIDE. | BUPROPION HYDROCHLORIDE | 1 | 100 MG, 2X/DAY, ONCE IN THE MORNING AND ONCE IN THE EVENING | 0 | 100 | MG | BID | ||||||||
| 125263322 | 12526332 | 8 | C | BUPROPION HYDROCHLORIDE. | BUPROPION HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125263322 | 12526332 | 9 | C | VENLAFAXINE HCL | VENLAFAXINE HYDROCHLORIDE | 1 | 150 MG, 1X/DAY | 0 | 150 | MG | QD | ||||||||
| 125263322 | 12526332 | 10 | C | LISINOPRIL. | LISINOPRIL | 1 | 10 MG, 1X/DAY | 0 | 10 | MG | QD | ||||||||
| 125263322 | 12526332 | 11 | C | ATORVASTATIN | ATORVASTATIN | 1 | 10MG (20MG, 1/2 TABLET) 1X/DAY | 0 | 10 | MG | TABLET | QD | |||||||
| 125263322 | 12526332 | 12 | C | HYDROXYZINE HCL | HYDROXYZINE HYDROCHLORIDE | 1 | Oral | 10 MG, 2X/DAY | 0 | 10 | MG | TABLET | BID | ||||||
| 125263322 | 12526332 | 13 | C | TRAZODONE HYDROCHLORIDE. | TRAZODONE HYDROCHLORIDE | 1 | Oral | 100 MG (50MG TABLET, 2 TABLETS), 1X/DAY AT BED | 0 | 100 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125263322 | 12526332 | 1 | Erectile dysfunction |
| 125263322 | 12526332 | 4 | Urinary tract disorder |
| 125263322 | 12526332 | 5 | Prostatic disorder |
| 125263322 | 12526332 | 6 | Hypertonic bladder |
| 125263322 | 12526332 | 7 | Post-traumatic stress disorder |
| 125263322 | 12526332 | 8 | Depression |
| 125263322 | 12526332 | 9 | Depression |
| 125263322 | 12526332 | 10 | Hypertension |
| 125263322 | 12526332 | 11 | Blood cholesterol abnormal |
| 125263322 | 12526332 | 13 | Sleep disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125263322 | 12526332 | Drug ineffective | |
| 125263322 | 12526332 | Drug interaction | |
| 125263322 | 12526332 | Intentional product misuse | |
| 125263322 | 12526332 | Spontaneous penile erection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |